Boston, MA – A new Perspective in the New England Journal of Medicine discusses the evolution of the U.S. Food and Drug Administration’s (FDA) Sentinel Initiative since its launch in 2008.  Coauthored by the scientists at the lead organization, the Harvard Pilgrim Health Care Institute, and at the FDA and the Duke Margolis Center for Health Policy, the piece describes the evolution of the Sentinel Initiative from a pilot program designed to assess potential drug-safety signals in insurance claims into a core component of the FDA’s evolving safety surveillance system.